Decadal mean regional hydrology. by Nic Gedney (19762301)

Subjects:

Contemporary mean inundation fraction in the Amazon basin. by Nic Gedney (19762301)

Subjects:

Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. by Nic Gedney (19762301)

Subjects:

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts. by Gillian P. McHugo (8965919)

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). by Philipp Winder (21615570)

Innovation and night light in large and small cities. by Saul Estrin (8629173)

Subjects:

Geographical distribution of large cities and small cities. by Saul Estrin (8629173)

Subjects:

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: